A Study of LY3305677 Compared With Placebo in Adult Participants With Obesity or Overweight

Inclusion Criteria:

W8M-MC-OXA1:

• Are males and females who agree to abide by the reproductive and contraceptiverequirements

W8M-MC-CWMM:

• Have a BMI ≥27 kilograms per square meter (kg/m²)

Exclusion Criteria:

W8M-MC-OXA1:

• Have any prior diagnosis of diabetes mellitus, that is type 2 diabetes mellitus (T2DM), or rare forms of diabetes mellitus, except gestational diabetes.

• Have any of the following cardiovascular conditions within 6 months prior toscreening:

• acute myocardial infarction

• cerebrovascular accident (stroke)

• unstable angina, or

• hospitalization due to congestive heart failure (CHF).

• Have a history of acute or chronic pancreatitis.

• Have a history of New York Heart Association (NYHA) Functional ClassificationI-IV CHF.

• Participants with hypertension who do not have well-controlled blood pressure (BP) (>140/90 mmHg), regardless of antihypertensive treatment. Participantsreceiving treatment for hypertension should be on a stable antihypertensiveregimen for at least 3 months prior to screening.

Note: If the investigator anticipates a need to add antihypertensive medication during the study, the participant should not be included in the ambulatory blood pressure monitoring (ABPM) procedures.

CWMM:

• Have a prior or planned surgical treatment for obesity, except prior liposuction orabdominoplasty, if performed >1 year prior to screening.

• Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history ofketoacidosis or hyperosmolar coma.

• Have poorly controlled hypertension.

• Have signs and symptoms of any liver disease other than nonalcoholic fatty liverdisease.

• Have a history of symptomatic gallbladder disease within the past 2 years.

• Have a lifetime history of suicide attempts.